Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Licenses Mutation Detection Technology From TwinStrand Biosciences

NEW YORK – Foundation Medicine said on Wednesday that it has signed a non-exclusive licensing agreement with TwinStrand Biosciences for a sequencing-based technology for rare mutation detection.

The agreement covers two foundational patent families from TwinStrand, a University of Washington spinout based in Seattle. 

The company's duplex sequencing technology independently tracks both strands of DNA molecules and then compares the paired sequences to eliminate errors. It can be used for residual cancer detection and genetic toxicology, among other applications. 

"We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration," Foundation Medicine CEO Cindy Perettie said in a statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.